168 related articles for article (PubMed ID: 26694250)
1. Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins.
Hermes N; Kewitz S; Staege MS
Curr Cancer Drug Targets; 2016; 16(5):400-14. PubMed ID: 26694250
[TBL] [Abstract][Full Text] [Related]
2. Preferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignancies.
Matsushita M; Yamazaki R; Ikeda H; Kawakami Y
Leuk Lymphoma; 2003 Mar; 44(3):439-44. PubMed ID: 12688312
[TBL] [Abstract][Full Text] [Related]
3. PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia.
Steinbach D; Pfaffendorf N; Wittig S; Gruhn B
Cancer Genet Cytogenet; 2007 Aug; 177(1):51-4. PubMed ID: 17693191
[TBL] [Abstract][Full Text] [Related]
4. The PRAME family of cancer testis antigens is essential for germline development and gametogenesis†.
Kern CH; Yang M; Liu WS
Biol Reprod; 2021 Aug; 105(2):290-304. PubMed ID: 33880503
[TBL] [Abstract][Full Text] [Related]
5. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
[TBL] [Abstract][Full Text] [Related]
6. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.
Epping MT; Wang L; Edel MJ; Carlée L; Hernandez M; Bernards R
Cell; 2005 Sep; 122(6):835-47. PubMed ID: 16179254
[TBL] [Abstract][Full Text] [Related]
7. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
Lee YK; Park UH; Kim EJ; Hwang JT; Jeong JC; Um SJ
Cancer Lett; 2017 Sep; 403():144-151. PubMed ID: 28634046
[TBL] [Abstract][Full Text] [Related]
8. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells.
Kewitz S; Staege MS
PLoS One; 2013; 8(2):e55897. PubMed ID: 23409080
[TBL] [Abstract][Full Text] [Related]
9. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
De Carvalho DD; Binato R; Pereira WO; Leroy JM; Colassanti MD; Proto-Siqueira R; Bueno-Da-Silva AE; Zago MA; Zanichelli MA; Abdelhay E; Castro FA; Jacysyn JF; Amarante-Mendes GP
Oncogene; 2011 Jan; 30(2):223-33. PubMed ID: 20838376
[TBL] [Abstract][Full Text] [Related]
10. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.
Wadelin F; Fulton J; McEwan PA; Spriggs KA; Emsley J; Heery DM
Mol Cancer; 2010 Aug; 9():226. PubMed ID: 20799951
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Detection of Cancer-Testis Antigen PRAME.
Lezcano C; Müller AM; Frosina D; Hernandez E; Geronimo JA; Busam KJ; Jungbluth AA
Int J Surg Pathol; 2021 Dec; 29(8):826-835. PubMed ID: 33890816
[TBL] [Abstract][Full Text] [Related]
13. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).
Bullinger L; Schlenk RF; Götz M; Botzenhardt U; Hofmann S; Russ AC; Babiak A; Zhang L; Schneider V; Döhner K; Schmitt M; Döhner H; Greiner J
Clin Cancer Res; 2013 May; 19(9):2562-71. PubMed ID: 23444226
[TBL] [Abstract][Full Text] [Related]
14. PRAME peptide-specific CD8
Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
[TBL] [Abstract][Full Text] [Related]
15. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells.
van Baren N; Chambost H; Ferrant A; Michaux L; Ikeda H; Millard I; Olive D; Boon T; Coulie PG
Br J Haematol; 1998 Sep; 102(5):1376-9. PubMed ID: 9753074
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo.
Tajeddine N; Gala JL; Louis M; Van Schoor M; Tombal B; Gailly P
Cancer Res; 2005 Aug; 65(16):7348-55. PubMed ID: 16103086
[TBL] [Abstract][Full Text] [Related]
17. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
18. Development of a New Highly Selective Monoclonal Antibody against Preferentially Expressed Antigen in Melanoma (PRAME) and Identification of the Target Epitope by Bio-Layer Interferometry.
Sivaccumar JP; Leonardi A; Iaccarino E; Corvino G; Sanguigno L; Chambery A; Russo R; Valletta M; Latino D; Capasso D; Doti N; Ruvo M; Sandomenico A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804612
[TBL] [Abstract][Full Text] [Related]
19. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
20. Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo.
Tajeddine N; Louis M; Vermylen C; Gala JL; Tombal B; Gailly P
Leuk Lymphoma; 2008 Jun; 49(6):1123-31. PubMed ID: 18452107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
